Cover Image

Evaluating the Evolving Real‐World Adverse Events of GLP ‐ 1RAs Using FDA Adverse Event Reporting System ( FAERS )

Fuente: Wiley Open Access

Saved in:

Bibliographic Details
Main Authors:	David Stone, Mary Playdon, Stephen D. Hursting, Aik Choon Tan
Format:	Artículo Open Access
Published:	Wiley 2026
Subjects:	Obesity
Online Access:	Acceder al recurso
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Indications and Adverse Events of Toradol: Based on FDA Adverse Event Reporting System (FAERS)
by: Jiaqi Guo, et al.
Published: (2026)

Descriptive Analysis of Ranolazine Adverse Events Reported in the FDA Adverse Event Reporting System (FAERS)
by: Nehad Jaser Ahmed
Published: (2026)

Descriptive Analysis of DALTEPARIN Adverse Events Reported in the FDA Adverse Event Reporting System (FAERS)
by: Nehad Jaser Ahmed
Published: (2026)

DOFETILIDE Descriptive Analysis of Adverse Events Reported in the FDA Adverse Event Reporting System (FAERS)
by: Nehad Jaser Ahmed
Published: (2026)

Prazosin Adverse Events: A Descriptive Analysis of the FDA Adverse Event Reporting System (FAERS)
by: Nehad Jaser Ahmed
Published: (2026)

Labetalol: A Descriptive Analysis of Adverse Events Reported in the FDA Adverse Event Reporting System (FAERS)
by: Nehad Jaser Ahmed
Published: (2026)

Addressing the risk of ocular complications of GLP ‐ 1RAs ; a multi‐disciplinary expert consensus
by: Patrice Carter, et al.
Published: (2025)

Future directions for quality of life research with second‐generation GLP ‐ 1RAs for obesity
by: Robert Hsu, et al.
Published: (2024)

HYDROCHLOROTHIAZIDE ADVERSE EVENTS A Descriptive Analysis of Adverse Events Reported in the FDA Adverse Event Reporting System (FAERS)
by: Nehad Jaser Ahmed
Published: (2026)

Adverse Event Profile of Spiramycin: A Comprehensive Pharmacovigilance Analysis of the FDA Adverse Event Reporting System (FAERS) Database
by: Nehad Jaser Ahmed
Published: (2026)

Descriptive Analysis of Amiloride Adverse Events Reported in the FDA Adverse Event Reporting System (FAERS): A Retrospective Pharmacovigilance Study
by: Nehad Jaser Ahmed
Published: (2026)

Descriptive Analysis of Alteplase Adverse Events Reported in the FDA Adverse Event Reporting System (FAERS): A Retrospective Pharmacovigilance Study
by: Nehad Jaser Ahmed
Published: (2026)

Association of Weight Loss Composition Following Metabolic‐Bariatric Surgery With Incident Major Adverse Cardiovascular Events and All‐Cause Mortality
by: Malou A. H. Nuijten, et al.
Published: (2025)

A Real‐World Pharmacovigilance Study of Fruquintinib Based on the FDA Adverse Event Reporting System ( FAERS ) Database
by: Yajing Xu, et al.
Published: (2025)

Low‐Dose Oral Minoxidil and Associated Adverse Events: Analyses of the FDA Adverse Event Reporting System ( FAERS ) With a Focus on Pericardial Effusions
by: Aditya K. Gupta, et al.
Published: (2024)

Letter to the Editor re “Cryolipolysis and Associated Health Outcomes, Adverse Events, and Satisfaction: A Systematic Review and Meta‐Analysis” Ravindran et al.
by: Nick Finer
Published: (2025)

Adverse Events Associated With Dabrafenib, Trametinib, and Their Combination Therapy: A Disproportionality Analysis of the FDA Adverse Event Reporting System ( FAERS ) Database
by: Zhenpo Zhang, et al.
Published: (2025)

Pharmacovigilance Analysis of Drug-Induced Rhabdomyolysis Based on the FDA Adverse Event Reporting System (FAERS)
by: Liang, Enpu
Published: (2025)

Adverse childhood experiences and appetitive traits in adolescence: A prospective cohort study
by: Alexandra Costa, et al.
Published: (2025)

Coexisting Asthma and Diabetes Are Associated With Adverse Metabolic and Inflammatory Profiles
by: Sixtus Aguree, et al.
Published: (2026)

Comparative effectiveness of combination therapy with SGLT ‐2 inhibitors and GLP ‐1 RAs compared with SGLT ‐2 inhibitors in individuals with type 2 diabetes: A prevalent new‐user cohort study
by: Gregor A. Maier, et al.
Published: (2026)

Association of Adverse Childhood Experiences and Metabolic Syndrome: A Systematic Review and Meta‐Analysis
by: Joohan Kim, et al.
Published: (2026)

Disparities in Prescription of Long‐Acting GLP‐1s
by: Katherine Wasden, et al.
Published: (2026)

A Real‐World Study on Adverse Reactions of Belimumab Based on the FDA Adverse Event Reporting System Database
by: Le Hai, et al.
Published: (2024)

Gestational Diabetes Mellitus and Adverse Maternal and Neonatal Health Outcomes: an Umbrella review of Meta‐Analyses
by: Jiseung Kang, et al.
Published: (2026)

Association of Glucagon‐Like Peptide‐1 Receptor Agonists With Cancer Risk in Older Adults With Type 2 Diabetes
by: Ying Lu, et al.
Published: (2025)

A Real‐World Pharmacovigilance Study of FDA Adverse Event Reporting System Events for Obeticholic Acid
by: Le Hai, et al.
Published: (2025)

Adverse event comparison between glucagon‐like peptide‐1 receptor agonists and other antiobesity medications following bariatric surgery
by: Jason M. Samuels, et al.
Published: (2024)

One Year of Exercise After Weight Loss Increases Postprandial GLP ‐1 Secretion in Contrast to Usual Activity or GLP ‐1 Receptor Agonist Treatment
by: Joachim Holt, et al.
Published: (2025)

Less frequent dosing of GLP‐1 receptor agonists as a viable weight maintenance strategy
by: Calvin C. Wu, et al.
Published: (2025)

Adverse cardiometabolic profile of women 6 months and 2 years after gestational hypertension
by: Yamema Esber, et al.
Published: (2025)

Relationships Between Metabolic and Bariatric Surgery and Adverse Kidney Outcomes: An Analysis of a Retrospective Cohort
by: Kevin C. Maki, et al.
Published: (2025)

Large‐Scale Plasma Proteomics Improves Prediction of Major Adverse Liver Outcomes in Individuals With MASLD
by: Hancheng Yu, et al.
Published: (2026)

GLP‐1 Receptor Agonists and Weight Loss: A Critical Review of Mechanisms
by: Giorgia Rutigliani, et al.
Published: (2026)

Combining GLP ‐1 Receptor Agonists and Health‐Behaviour and Lifestyle Therapy Yields Higher Adherence and Reduces Session Needs for Successful Weight Management in Adolescence: An Observational Real‐World Single‐Center Study
by: Julia Lischka, et al.
Published: (2026)

GLP‐1 receptor agonists and retained gastric content: Is it much ado about nothing?
by: Michael Camilleri
Published: (2025)

Balancing procedural safety and therapeutic continuity: GLP‐1 receptor agonists and upper endoscopy
by: Lien‐Chung Wei, et al.
Published: (2025)

Drug‐Associated Ketoacidosis: A Comprehensive Disproportionality Analysis Based on the FAERS Database
by: Pengqiang Du, et al.
Published: (2026)

Evaluating appetite/satiety hormones and eating behaviours as predictors of weight loss maintenance with GLP‐1RA therapy in adolescents with severe obesity
by: Megan O. Bensignor, et al.
Published: (2024)

ADHD medications and drug withdrawal: A pharmacovigilance study using the FDA Adverse Event Reporting System (FAERS) database
by: Takumi Ebina, et al.
Published: (2026)